← FDA DRUG APPROVALS

FDA ANDA · ANDA090649

NIFEDIPINE

Sponsor: AUROBINDO PHARMA USA

APPLICATION
ANDA090649
TYPE
ANDA
ORIGINAL APPROVAL
2010-06-21
LATEST ACTION
2016-02-03
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Discontinued

Products

NIFEDIPINEDiscontinued
NIFEDIPINE 90MG · TABLET, EXTENDED RELEASE · ORAL
NIFEDIPINEDiscontinued
NIFEDIPINE 30MG · TABLET, EXTENDED RELEASE · ORAL
NIFEDIPINEDiscontinued
NIFEDIPINE 60MG · TABLET, EXTENDED RELEASE · ORAL

Approval history

2016-02-03Labeling · Supplement 13 · standardAP
2015-01-20Labeling · Supplement 8 · standardAP
2015-01-20Labeling · Supplement 11 · standardAP
2013-08-16Labeling · Supplement 6 · standardAP
2012-10-29Manufacturing (CMC) · Supplement 5AP
2011-07-29Labeling · Supplement 3AP
2010-06-21OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →